{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T22:41:27Z","timestamp":1789166487626,"version":"build-2803163510"},"reference-count":83,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Europe"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.lanepe.2026.101659","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:11:19Z","timestamp":1773965479000},"page":"101659","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Oncolytic viruses and neoantigen vaccines: opportunities and challenges in priming antitumour immunity"],"prefix":"10.1016","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8771-0838","authenticated-orcid":false,"given":"Andr\u00e9","family":"Mansinho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Albuquerque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiliano","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lanepe.2026.101659_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1324744","article-title":"Oncolytic vaccinia virus and cancer immunotherapy","volume":"14","author":"Xu","year":"2024","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.lanepe.2026.101659_bib2","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41571-024-00867-1","article-title":"Personalized neoantigen mRNA vaccine mitigates melanoma recurrence","volume":"21","author":"Killock","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"10.1016\/j.lanepe.2026.101659_bib3","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/sj.mt.6300108","article-title":"History of oncolytic viruses: genesis to genetic engineering","volume":"15","author":"Kelly","year":"2007","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101659_bib5","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41392-023-01674-3","article-title":"Therapeutic cancer vaccines: advancements, challenges, and prospects","volume":"8","author":"Fan","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101659_bib6","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1115641","article-title":"First oncolytic virus approved for melanoma immunotherapy","volume":"5","author":"Pol","year":"2015","journal-title":"Oncoimmunology"},{"issue":"4","key":"10.1016\/j.lanepe.2026.101659_bib7","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3390\/biom14040503","article-title":"Recent findings on therapeutic cancer vaccines: an updated review","volume":"14","author":"Sheikhlary","year":"2024","journal-title":"Biomolecules"},{"issue":"10427","key":"10.1016\/j.lanepe.2026.101659_bib8","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.lanepe.2026.101659_bib9","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.3390\/ijms25021180","article-title":"Oncolytic virotherapy: a new paradigm in cancer immunotherapy","volume":"25","author":"Volovat","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101659_bib10","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.01526-22","article-title":"Molecular mechanisms of poxvirus evolution","volume":"14","author":"Brennan","year":"2023","journal-title":"mBio"},{"issue":"2","key":"10.1016\/j.lanepe.2026.101659_bib11","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3171\/2023.6.JNS23243","article-title":"Oncolytic viral therapy: a review and promising future directions","volume":"140","author":"Reddy","year":"2024","journal-title":"J Neurosurg"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101659_bib12","article-title":"Enhancing cancer therapy: the integration of oncolytic virus therapy with diverse treatments","volume":"24","author":"Zhuo","year":"2024","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.lanepe.2026.101659_bib13","series-title":"Springer eBooks","first-page":"429","article-title":"Oncolytic viruses and viral gene therapy vectors: principles of safety","author":"Spiesschaert","year":"2023"},{"key":"10.1016\/j.lanepe.2026.101659_bib14","doi-asserted-by":"crossref","DOI":"10.37349\/ei.2025.1003204","article-title":"The dual promise of oncolytic viruses: selective targeting and therapeutic enhancement in cancer treatment","volume":"5","author":"Aljabali","year":"2025","journal-title":"Explor Immunol"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101659_bib15","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41392-023-01407-6","article-title":"Oncolytic virotherapy: basic principles, recent advances and future directions","volume":"8","author":"Lin","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"9","key":"10.1016\/j.lanepe.2026.101659_bib16","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: a new class of immunotherapy drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.lanepe.2026.101659_bib17","article-title":"Evolving role of oncolytic virotherapy: challenges and prospects in clinical practice","volume":"5","author":"Moaven","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.lanepe.2026.101659_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.790150","article-title":"Oncolytic virotherapy: from bench to bedside","volume":"9","author":"Yang","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.lanepe.2026.101659_bib19","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3389\/fimmu.2017.00555","article-title":"Oncolytic immunotherapy: conceptual evolution, current strategies, and future perspectives","volume":"8","author":"Guo","year":"2017","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.lanepe.2026.101659_bib20","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s40265-023-01846-z","article-title":"Nadofaragene firadenovec: first approval","volume":"83","author":"Lee","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.lanepe.2026.101659_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1272351","article-title":"Recent progress in combination therapy of oncolytic vaccinia virus","volume":"15","author":"Mirbahari","year":"2024","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.lanepe.2026.101659_bib22","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001486","article-title":"Clinical landscape of oncolytic virus research in 2020","volume":"8","author":"Macedo","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"6","key":"10.1016\/j.lanepe.2026.101659_bib23","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.3390\/cancers13061383","article-title":"Talimogene Laherparepvec (T-VEC): an intralesional cancer immunotherapy for advanced melanoma","volume":"13","author":"Ferrucci","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.lanepe.2026.101659_bib24","doi-asserted-by":"crossref","first-page":"5767","DOI":"10.3390\/v7112905","article-title":"Oncolytic replication of E1b-deleted adenoviruses","volume":"7","author":"Cheng","year":"2015","journal-title":"Viruses"},{"key":"10.1016\/j.lanepe.2026.101659_bib25","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3389\/fonc.2014.00167","article-title":"Activated ras signaling pathways and reovirus oncolysis: an update on the mechanism of preferential reovirus replication in cancer cells","volume":"4","author":"Gong","year":"2014","journal-title":"Front Oncol"},{"key":"10.1016\/j.lanepe.2026.101659_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/OV.S186337","article-title":"Virus-receptor interactions and virus neutralization: insights for oncolytic virus development","volume":"9","author":"Jayawardena","year":"2020","journal-title":"Oncolytic Virother"},{"issue":"9","key":"10.1016\/j.lanepe.2026.101659_bib27","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41573-019-0029-0","article-title":"Optimizing oncolytic virotherapy in cancer treatment","volume":"18","author":"Harrington","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"10.1016\/j.lanepe.2026.101659_bib30","doi-asserted-by":"crossref","first-page":"880","DOI":"10.3390\/vaccines13080880","article-title":"Oncolytic Herpes simplex virus therapy: latest advances, core challenges, and future outlook","volume":"13","author":"Zheng","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.lanepe.2026.101659_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1308890","article-title":"Oncolytic virotherapy in cancer treatment: challenges and optimization prospects","volume":"14","author":"Chen","year":"2023","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.lanepe.2026.101659_bib32","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1007\/s12274-021-4031-6","article-title":"Emerging systemic delivery strategies of oncolytic viruses: a key step toward cancer immunotherapy","volume":"15","author":"Ban","year":"2022","journal-title":"Nano Res"},{"issue":"3","key":"10.1016\/j.lanepe.2026.101659_bib33","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41571-022-00719-w","article-title":"Therapy with oncolytic viruses: progress and challenges","volume":"20","author":"Shalhout","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.lanepe.2026.101659_bib28","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40425-016-0116-2","article-title":"Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study","volume":"4","author":"Kaufman","year":"2016","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.lanepe.2026.101659_bib29","doi-asserted-by":"crossref","first-page":"805629","DOI":"10.1155\/2012\/805629","article-title":"Systemic delivery of oncolytic viruses: hopes and hurdles","volume":"2012","author":"Ferguson","year":"2012","journal-title":"Adv Virol"},{"issue":"25","key":"10.1016\/j.lanepe.2026.101659_bib34","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lanepe.2026.101659_bib35","article-title":"429\u2005Long-term analysis of MASTERKEY-265 phase 1b trial of talimogene laherparepvec (T-VEC) plus pembrolizumab in patients with unresectable stage IIIB-IVM1c melanoma","volume":"8","author":"Long","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/j.lanepe.2026.101659_bib36","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1200\/JCO.22.00343","article-title":"Randomized, double-blind, placebo-controlled, global phase III trial of talimogene laherparepvec combined with pembrolizumab for advanced melanoma","volume":"41","author":"Chesney","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lanepe.2026.101659_bib37","article-title":"The combination therapy of oncolytic virotherapy","volume":"15","author":"Wang","year":"2024","journal-title":"Front Pharmacol"},{"issue":"16","key":"10.1016\/j.lanepe.2026.101659_bib38","doi-asserted-by":"crossref","first-page":"4178","DOI":"10.3390\/cancers15164178","article-title":"Oncolytic viruses and immune checkpoint inhibitors: the \u201cHot\u201d new power couple","volume":"15","author":"Lovatt","year":"2023","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.lanepe.2026.101659_bib39","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/S1470-2045(24)00079-2","article-title":"LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1\/2 study","volume":"25","author":"Musher","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.lanepe.2026.101659_bib40","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1200\/JCO-25-01346","article-title":"RP1 combined with Nivolumab in advanced Anti\u2013PD-1\u2013Failed Melanoma (IGNYTE)","volume":"43","author":"Wong","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lanepe.2026.101659_bib41","article-title":"993MO A phase I, open-label, multicenter, dose escalation safety and tolerability study of oncolytic virus OVV-01 in advanced solid tumors","volume":"35","author":"Yang","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.lanepe.2026.101659_bib42","doi-asserted-by":"crossref","first-page":"S677","DOI":"10.1016\/j.annonc.2024.08.1053","article-title":"994MO the updated report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15\/R\u03b1 payloads, in patients with advanced solid tumors","volume":"35","author":"Shen","year":"2024","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101659_bib43","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41591-024-03334-7","article-title":"Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial","volume":"31","author":"Lopez","year":"2025","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.lanepe.2026.101659_bib44","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.cell.2020.08.053","article-title":"A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer","volume":"183","author":"Ott","year":"2020","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.lanepe.2026.101659_bib45","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/s41571-024-00902-1","article-title":"Cancer mRNA vaccines: clinical advances and future opportunities","volume":"21","author":"Sayour","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"10.1016\/j.lanepe.2026.101659_bib46","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nri.2017.131","article-title":"Towards personalized, tumour-specific, therapeutic vaccines for cancer","volume":"18","author":"Hu","year":"2018","journal-title":"Nat Rev Immunol"},{"issue":"7662","key":"10.1016\/j.lanepe.2026.101659_bib47","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature23003","article-title":"Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer","volume":"547","author":"Sahin","year":"2017","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.lanepe.2026.101659_bib48","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.lanepe.2026.101659_bib49","doi-asserted-by":"crossref","first-page":"976","DOI":"10.3390\/vaccines13090976","article-title":"Messenger RNA and plasmid DNA vaccines for the treatment of cancer","volume":"13","author":"Moseman","year":"2025","journal-title":"Vaccines"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101659_bib50","doi-asserted-by":"crossref","DOI":"10.1186\/s43556-024-00241-8","article-title":"Cancer vaccines: platforms and current progress","volume":"6","author":"Lei","year":"2025","journal-title":"Mol Biomed"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101659_bib51","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-022-01247-x","article-title":"Cancer vaccines as promising immuno-therapeutics: platforms and current progress","volume":"15","author":"Liu","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.lanepe.2026.101659_bib52","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1029069","article-title":"mRNA vaccines for cancer immunotherapy","volume":"13","author":"Vishweshwaraiah","year":"2022","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.lanepe.2026.101659_bib53","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrc.2016.154","article-title":"Targeting neoantigens to augment antitumour immunity","volume":"17","author":"Yarchoan","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.lanepe.2026.101659_bib54","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/s41586-024-08508-4","article-title":"RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer","volume":"639","author":"Sethna","year":"2025","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.lanepe.2026.101659_bib55","article-title":"State-Of-The-Art advancements on cancer vaccines and biomarkers","volume":"44","author":"Strum","year":"2024","journal-title":"J Clin Oncol"},{"issue":"suppl_5","key":"10.1016\/j.lanepe.2026.101659_bib56","first-page":"LBA53","article-title":"IO102-IO103 cancer vaccine plus pembrolizumab for first-line (1L) advanced melanoma: primary phase III results (IOB-013\/KN-D18)","volume":"36","author":"Hassel","year":"2025","journal-title":"Ann Oncol"},{"issue":"suppl_5","key":"10.1016\/j.lanepe.2026.101659_bib57","doi-asserted-by":"crossref","first-page":"S844","DOI":"10.1016\/j.annonc.2025.08.2146","article-title":"1515MO clinical outcomes and PD-L1 expression analyses from a trial of mRNA-4359 plus pembrolizumab in checkpoint inhibitor-resistant\/refractory (CPI-R\/R) melanoma","volume":"36","author":"Pinato","year":"2025","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.lanepe.2026.101659_bib58","first-page":"197","article-title":"Sipuleucel-T (provenge) injection: the first immunotherapy agent (vaccine) for hormone-refractory prostate cancer","volume":"36","author":"Anassi","year":"2011","journal-title":"P T"},{"issue":"16","key":"10.1016\/j.lanepe.2026.101659_bib59","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/j.vaccine.2021.03.038","article-title":"mRNA vaccines manufacturing: Challenges and bottlenecks","volume":"39","author":"Rosa","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.lanepe.2026.101659_bib60","article-title":"Advances in preclinical and clinical studies of oncolytic virus combination therapy","volume":"15","author":"Du","year":"2025","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.lanepe.2026.101659_bib61","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41571-021-00490-4","article-title":"Advancing oncolytic virus therapy by understanding the biology","volume":"18","author":"Kaufman","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"10.1016\/j.lanepe.2026.101659_bib62","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.3390\/cancers13123058","article-title":"Nectin-1 expression correlates with the susceptibility of malignant melanoma to oncolytic Herpes Simplex virus in vitro and in vivo","volume":"13","author":"Schwertner","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.lanepe.2026.101659_bib63","doi-asserted-by":"crossref","first-page":"LBA9512","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA9512","article-title":"Individualized neoantigen therapy mRNA-4157 (V940) plus pembrolizumab in resected melanoma: 3-year update from the mRNA-4157-P201 (KEYNOTE-942) trial","volume":"42","author":"Weber","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lanepe.2026.101659_bib64","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1448489","article-title":"Emerging prospects of mRNA cancer vaccines: mechanisms, formulations, and challenges in cancer immunotherapy","volume":"15","author":"Laila","year":"2024","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.lanepe.2026.101659_bib65","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3390\/life15020283","article-title":"Towards the prediction of responses to cancer immunotherapy: a multi-omics review","volume":"15","author":"Tao","year":"2025","journal-title":"Life"},{"issue":"4","key":"10.1016\/j.lanepe.2026.101659_bib66","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1177\/2168479017738979","article-title":"A comparative safety profile assessment of oncolytic virus therapy based on clinical trials","volume":"52","author":"Matsuda","year":"2018","journal-title":"Ther Innov Regul Sci"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101659_bib67","doi-asserted-by":"crossref","DOI":"10.1186\/s12985-021-01630-z","article-title":"Efficacy and safety of oncolytic viruses in advanced or metastatic cancer: a network meta-analysis","volume":"18","author":"Xie","year":"2021","journal-title":"Virol J"},{"key":"10.1016\/j.lanepe.2026.101659_bib68","article-title":"Personalized cancer vaccines in the clinical trial pipeline","author":"Iamukova","year":"2025","journal-title":"Asia Pac J Clin Oncol"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101659_bib69","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-024-06033-6","article-title":"mRNA vaccines in the context of cancer treatment: from concept to application","volume":"23","author":"Fu","year":"2025","journal-title":"J Transl Med"},{"key":"10.1016\/j.lanepe.2026.101659_bib70","first-page":"253","article-title":"Oncolytic adenoviruses for cancer immunotherapy","volume":"Vol. 122","author":"Hemminki","year":"2014"},{"key":"10.1016\/j.lanepe.2026.101659_bib71","doi-asserted-by":"crossref","DOI":"10.1093\/rb\/rbaf023","article-title":"Development of lyophilized mRNA-LNPs with high stability and transfection efficiency in specific cells and tissues","volume":"12","author":"Wang","year":"2025","journal-title":"Regen Biomater"},{"issue":"19","key":"10.1016\/j.lanepe.2026.101659_bib72","doi-asserted-by":"crossref","DOI":"10.3390\/ijms251910603","article-title":"Comprehensive optimization of a freeze-drying process achieving enhanced long-term stability and in vivo performance of lyophilized mRNA-LNPs","volume":"25","author":"Alejo","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"12","key":"10.1016\/j.lanepe.2026.101659_bib73","doi-asserted-by":"crossref","first-page":"4327","DOI":"10.1039\/D2BM02031A","article-title":"Successful batch and continuous lyophilization of mRNA LNP formulations depend on cryoprotectants and ionizable lipids","volume":"11","author":"Lamoot","year":"2023","journal-title":"Biomater Sci"},{"issue":"3","key":"10.1016\/j.lanepe.2026.101659_bib74","doi-asserted-by":"crossref","DOI":"10.1063\/5.0150345","article-title":"Microfluidic approaches for producing lipid-based nanoparticles for drug delivery applications","volume":"4","author":"Piunti","year":"2023","journal-title":"Biophys Rev"},{"issue":"12","key":"10.1016\/j.lanepe.2026.101659_bib75","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat Rev Mater"},{"key":"10.1016\/j.lanepe.2026.101659_bib76","article-title":"Advances and challenges in neoantigen prediction for cancer immunotherapy","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.lanepe.2026.101659_bib77","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1158\/2326-6066.CIR-19-0401","article-title":"pVACtools: a computational toolkit to identify and visualize cancer neoantigens","volume":"8","author":"Hundal","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.lanepe.2026.101659_bib78","doi-asserted-by":"crossref","first-page":"W449","DOI":"10.1093\/nar\/gkaa379","article-title":"NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data","volume":"48","author":"Reynisson","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.lanepe.2026.101659_bib79","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1261243","article-title":"Amplifying mRNA vaccines: potential versatile magicians for oncotherapy","volume":"14","author":"Hu","year":"2023","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101659_bib80","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3390\/pathogens12010138","article-title":"Self-Amplifying RNA vaccine candidates: alternative platforms for mRNA vaccine development","volume":"12","author":"Schmidt","year":"2023","journal-title":"Pathogens"},{"issue":"14","key":"10.1016\/j.lanepe.2026.101659_bib81","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.3390\/cancers17142296","article-title":"Cell carriers for oncolytic virus delivery: prospects for systemic administration","volume":"17","author":"Sarkisova","year":"2025","journal-title":"Cancers"},{"issue":"14","key":"10.1016\/j.lanepe.2026.101659_bib82","doi-asserted-by":"crossref","first-page":"6900","DOI":"10.3390\/ijms26146900","article-title":"Systemic delivery strategies for oncolytic viruses: advancing targeted and efficient tumor therapy","volume":"26","author":"Xia","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101659_bib83","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.232654","article-title":"Intratumoral injection of immunotherapeutics: state of the art and future directions","volume":"312","author":"Sheth","year":"2024","journal-title":"Radiology"},{"key":"10.1016\/j.lanepe.2026.101659_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114505","article-title":"Image-guided intratumoral immunotherapy: developing a clinically practical technology","volume":"189","author":"Som","year":"2022","journal-title":"Adv Drug Deliv Rev"}],"container-title":["The Lancet Regional Health - Europe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776226000712?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776226000712?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T08:35:31Z","timestamp":1777883731000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666776226000712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":83,"alternative-id":["S2666776226000712"],"URL":"https:\/\/doi.org\/10.1016\/j.lanepe.2026.101659","relation":{},"ISSN":["2666-7762"],"issn-type":[{"value":"2666-7762","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oncolytic viruses and neoantigen vaccines: opportunities and challenges in priming antitumour immunity","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Europe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2026.101659","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2026.101634","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2023.100699","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2026.101694","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2026.101599","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2026.101590","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101659"}}